Skip to main content
MNKD logo

MNKD · Mannkind Corp

Track MNKD — free
$4.07 +0.12 (+2.91%)
Market Cap
$1.27B
Shares
321.64M
Volume · Nov 20 408.27K Avg daily vol (3M) 3.94M

Price & Indicators

 

Key stats

Close
$3.95
Open
$4.07
Day range
$3.89–4.08
52-week closing range
$2.28–6.21
Average volume, 30 days
3.5M
Short interest
26.2M · 8.2% of shares · 10.3 days
Short volume, last session
38%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
Q4 revenue expected at about $38 million, plus or minus

Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback.

4 source passages
We expect Q4 to be about $38 million in revenue. It'll be plus or minus. That trial has now been the foundation with the FDA to advance into Phase 2 here in the U.S. We just met with the FDA. Open the document at this passage
Nov 5
Earnings call
ReadyFlow adoption accelerates as fourth-quarter profitability nears

Mankind Corporation reported third-quarter revenue of $101.9 million, up 24%, while roughly 75% of Furosix shipments had moved to ReadyFlow by late October. It expects record fourth-quarter revenue to drive profitability.

3 source passages
Third quarter total revenue was $101.9 million, up 24%, from $82.1 million in the third quarter of 2025. Furosix ReadyFlow was approved and by late October, roughly 75% of Furosix shipments had moved to ReadyFlow, exceeding our internal expectations by several quarters. We expect record revenue in Q4 will drive us to profitability as we close out the year Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 27% as net loss reached $58.9 million

For the nine months ended September 30, 2026, Mannkind reported 27% total revenue growth, a $58.9 million net loss and a $36.9 million, or 73%, increase in commercial product gross profit.

Revenue $101.87M ▲ 24.0% Net loss $23.22M Diluted EPS -$0.07
Read from the MD&A section
4 source passages
### Three and nine months ended September 30, 2026 and 2025 Total revenues | 301,416 | 237,011 | 64,405 | | 27% Cash used in operating activities consisted of a net loss of $58.9 million offset by non-cash adjustments of $58.8 million and a net decrease in cash flow from operating assets and liabilities of $58.2 million. Commercial product gross profit increased by $36.9 million, or 73%, for the nine months ended September 30, 2026 compared to the same period in the prior year. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 24% as Furoscix ReadyFlow gains adoption

MannKind reported Q3 2026 total revenues of $101.9 million, up 24% from Q3 2025, as commercial product revenue reached $45.0 million. Furoscix ReadyFlow shipments began in mid-September and represented approximately 75% of current weekly Furoscix shipments.

Financial results
4 source passages
Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 Furoscix ReadyFlow was approved and shipments commenced mid-September Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix shipments Open the document at this passage
Oct 20
Investor event
Chardan Healthcare Conference

Mannkind said inhaled natetanib is entering phase 2 with about 140 patients testing two doses in about 12 or 13 countries, after initial dosing showed no diarrhea or cough-related discontinuations.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$413.37M
Trailing 12 months
Net income (TTM)
−$74.82M
Trailing 12 months
Revenue growth YoY
+24.0%
Year over year
Operating margin
-2.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$222.84M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.7%
Year over year · more shares
Price change (1Y)
-21.0%
Trailing year
Short interest
8.2%
Latest settlement · 10.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Third-quarter revenue rose 24%, commercial product revenue rose 102%, and ReadyFlow adoption reached approximately 75% of current weekly Furoscix shipments. Management expects Q4 and 2027 profitability, but the company reported a $23.2 million GAAP net loss, lower gross margin, and sharply higher selling, general and administrative expenses.

Bullish
  • + Q3 total revenue increased 24% to $101.9 million new
  • + Commercial product revenue increased 102% to $45.0 million new
  • + ReadyFlow reached approximately 75% of current weekly Furoscix shipments new
  • + Furoscix is expected to generate more fourth-quarter revenue than in the first half of 2026 new
  • + Average monthly new-to-brand Afrezza prescriptions increased approximately 80% new
  • + Management expects profitability in the fourth quarter and on an annual basis in 2027 new
Bearish
  • − Q3 GAAP net loss was $23.2 million versus $8.0 million of net income in the prior-year quarter new
  • − Commercial cost of goods sold increased to $11.2 million and gross margin declined new
  • − Selling, general and administrative expenses increased 111% to $61.4 million new
  • − Collaboration and services revenue declined 27% new
  • − Afrezza's adult business underperformed this year new
  • − Pediatric Afrezza prescription growth is running ahead of revenue while paid insurance conversion remains incomplete new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg +11%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 42%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +23%
trailing
6-month return +12%
trailing
YTD return −30%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.15% of shares out · ▲ +2.9% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
251 holders — mid 3-yr range
Squeeze score 81
high risk · 0–100
Fundamentals
Fair
Revenue growth +22%
Y/Y
EPS growth −80%
Y/Y
Free cash flow $13.7M
Balance sheet $279.8M
net debt
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −63%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
in 2027
Milestones from Lenapeg DPI $15M
from 2027 through 2030
Revenue from the UT license agreement at least $1B
Q4
Furosix revenue $38M
2027 through 2030
UT license agreement revenue at least $1B
Previous outlook earlier release · from the Earnings Call filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

FURO6 revenue · full-year 2026 $110M – $120M
FURO6 sales · this year $110M – $120M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
42% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.15% of shares out · ▲ +2.9% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
251 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $4 · 42% Range high $6
vs 200-day avg +9% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and investments $96.6M as of September 30, 2026 —
Non-GAAP adjusted net (loss) income non-GAAP -10.41M Nine Months Ended September 30, 2026 —
Pediatric patients treated with Afrezza 2,000 since launch —
Share of Furoscix shipments transitioned to ReadyFlow 75% by late October —
Integrated Delivery Networks doses purchased increase 36% Q2 2026 —
Nephrology units dispensed increase 67% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MNKD
Mannkind Corp
this stock
$1.27B -30.3% +22.2% — 8.2%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
251
% held
59.9%
Net QoQ
+10.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
168
View
Short & Settlement
Short Interest Rising
Shares short
26.2M
Days to cover
10.3d
Change
+742.1K sh
View
Short Volume
Short vol %
38%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$3.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
49.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$349.0M
Net income (FY)
$5.9M
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
20

Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback.

View
Proposed Sales
Value
$128.5K
Shares
39.1K
Filed
Sep 25, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
MannKind to Participate in Upcomi…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
MNKD -5.1% +23.4% +11.9% +12.9% -30.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.4% +29.7% +17.5% +18.1% -35.3%
Key facts CIK 899460 CUSIP 56400P706 13F (30d) 262 filings 232 filers Visit website Investor relations